FindTrial
Sign In

Histopathological spectrum of gastrointestinal lesion in gastrointestinal cancer

Histopathological Spectrum of Gastrointestinal Lesion and Her2/neu expression in Gastrointestinal Adenocarcinoma:A Cross-Sectional Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/12/048471
Enrollment
76
Registered
2022-12-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C269- Malignant neoplasm of ill-definedsites within the digestive system

Interventions

Intervention1: Nil: Nil

Sponsors

Rohilkhand Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All small and large biopsies of lesions including oesophagus, stomach, small intestine and the large intestine of any age and gender received in pathology department till the appropriate sample size is achieved.

Exclusion criteria

Exclusion criteria: 1. Biopsies reported or inadequate. 2. Biopsies from oral cavity, pharynx and anus.

Design outcomes

Primary

MeasureTime frame
To study the prevalence and distribution of various gastrointestinal lesions according to clinicopathological parameters.Timepoint: Baseline—

Secondary

MeasureTime frame
To evaluate the HER2/neu protein over expression in different gastrointestinal adenocarcinoma.Timepoint: Baseline—

Countries

India

Contacts

Public ContactDr Meghna Yadav

Rohilkhand Medical College and Hospital, Bareilly.

anjanaarya.singh15@gmail.com9412125824

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026